REG - Oxford Biomedica PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

28/11/2016 10:10

RNS Number : 3011Q
Oxford Biomedica PLC
28 November 2016
Director Dealings / Market Share Purchase
Oxford, UK - 28 November 2016:Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the Group, on Friday, 25 November 2016, acquired ordinary shares in the Group as set out below, under the market share purchase agreement outlined in the Group's announcement on 15 December 2015.
 
Under the market share purchase agreement, one-third of Dr Tallarigo's fees as Chairman, after tax, are to be used to purchase shares in Oxford BioMedica PLC on a monthly basis at the prevailing market price. 
Interest after purchase
Director / PDMR
Title
Price per share (p)
Number of Ordinary Shares acquired
Number of Ordinary Shares
% of total
issued share capital
Dr Lorenzo Tallarigo
Chairman
3.5p
75,417
1,588,116
0.05%
The issued share capital of the Group is 3,087,953,461 ordinary 1p shares.
-Ends-
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
Tel: +44 (0)20 3709 5700
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHBGBDBXGDBGLI